Zhihui Zhang, Xuesong Liu, Rong Zhang, Dongdong Liu, Chun Yang, Sibei Chen, Yimin Li, Xiaoqing Liu
{"title":"危重患者下呼吸道巨细胞病毒检测:揭示增强的潜在益处","authors":"Zhihui Zhang, Xuesong Liu, Rong Zhang, Dongdong Liu, Chun Yang, Sibei Chen, Yimin Li, Xiaoqing Liu","doi":"10.1186/s13054-025-05456-x","DOIUrl":null,"url":null,"abstract":"<p>We were highly interested in reading the clinical research conducted by Kim et al. [1]. This study is a single-center, retrospective clinical cohort investigation with a large sample size, focusing primarily on the significance of lower respiratory tract (LRT) cytomegalovirus (CMV) positivity in the prognosis of critically ill patients. The research departs from the traditional focus on CMV reactivation in blood samples and examines the epidemiological characteristics of critically ill patients with CMV positivity in the LRT. These findings demonstrate CMV positivity in the LRT as a significant risk factor for mortality in patients with critical illness. However, the detection of CMV positivity in the LRT may hold greater significance, and the comprehensiveness of this study could be further enhanced through additional refinements.</p><p>First, the direct definition of CMV detection positivity in the LRT as “reactivation” is debatable. Current CMV-related definitions do not explicitly address this issue [2, 3]. Moreover, the prevailing view is that “reactivation” should be defined based on the premise of CMV seropositivity (IgG) and the detection of a certain CMV viral load in blood samples [2,3,4]. Therefore, the term “CMV detection positivity” is more accurate. Additionally, the CMV viral load may vary among different LRT specimens. Theoretically, the CMV viral load in bronchoalveolar lavage fluid is higher than that in endotracheal aspirates, which may subsequently have different impacts on clinical outcomes. It is necessary to further evaluate the CMV detection positivity and viral load in different LRT specimens and their associations with clinical outcomes.</p><p>Second, of particular importance is the observation that CMV detection in the LRT precede its detection in the blood, especially in patients with septic shock [4, 5]. This phenomenon is likely attributed to the high levels of inflammation associated with sepsis. Under conditions of elevated inflammation, latent CMV infection can be reactivated, subsequently leading to CMV-related injury [6]. Notably, clinical studies have demonstrated a close association between CMV reactivation and pulmonary fibrosis in patients with acute respiratory distress syndrome [7], while animal studies have shown that CMV reactivation can induce pulmonary fibroproliferation [8], suggesting that CMV reactivation may trigger lung injury. Therefore, assessing CMV antiviral therapy based on the LRT findings may hold greater value, including both prophylactic and preemptive treatment strategies.</p><p>Third, subgroup analyses should be conducted to distinguish patients with different immune statuses, including immunosuppressed and non-immunosuppressed individuals, because the incidence of active CMV infection varies across different immune backgrounds, particularly with a higher rate observed in immunosuppressed patients [2,3,4, 9]. Sepsis patients, who are in an acute state of immunosuppression, merit special attention [10]. In this study, the incidence of sepsis exceeded 70%, and high levels of inflammation were found to be more likely to trigger reactivation of latent CMV infection. The early stages (overwhelming inflammation) and the later stages (refractory inflammation, immunosuppression, and risk of secondary infections) of sepsis are both conducive to CMV reactivation [10,11,12,13,14]. Our research demonstrates that the incidence of CMV reactivation is at least 30% higher among critically ill patients with sepsis compared to those without, and sepsis has been identified as an independent risk factor for CMV reactivation [9, 15].</p><p>Fourth, the issue of CMV co-infection with other pathogens should be addressed by employing next-generation sequencing of pathogens to enhance the accuracy of pathogen detection. It is also necessary to distinguish between CMV and colonizing or pathogenic bacteria. In addition, the impact of combined antiviral treatment against CMV and therapy for other pathogens on prognosis needs to be further clarified. Decades of research have shown that CMV infection and reactivation have a negative impact on critically ill patients. Nevertheless, our understanding of the role of CMV positivity in different specimens remains limited. Therefore, we believe that in-depth research into CMV detection in the LRT is of significant importance.</p><p>In summary, the study by Kim et al. revealed the adverse clinical outcomes associated with the detection of CMV in the LRT among critically ill patients, thereby contributing to the advancement of the field. A detailed and nuanced exploration of the aforementioned issues is crucial for fully elucidating the complex interplay between LRT CMV positivity and the prognosis of critically ill patients. Future studies should further investigate these complexities to refine our understanding and potentially guide the development of more effective therapeutic strategies.</p><p>No datasets were generated or analysed during the current study.</p><dl><dt style=\"min-width:50px;\"><dfn>CMV:</dfn></dt><dd>\n<p>Cytomegalovirus</p>\n</dd><dt style=\"min-width:50px;\"><dfn>LRT:</dfn></dt><dd>\n<p>Lower Respiratory Tract</p>\n</dd></dl><ol data-track-component=\"outbound reference\" data-track-context=\"references section\"><li data-counter=\"1.\"><p>Kim JY, Lee CM, Ahn YH, et al. Cytomegalovirus reactivation in the lower respiratory tract as an independent risk factor for mortality in critically ill patients[J]. Crit Care. 2025;29(1):177. https://doi.org/10.1186/s13054-025-05324-8.</p><p>Article PubMed PubMed Central Google Scholar </p></li><li data-counter=\"2.\"><p>Fernández S, Castro P, Azoulay E. What intensivists need to know about cytomegalovirus infection in immunocompromised ICU patients[J]. Intensive Care Med. 2025;51(1):39–61. https://doi.org/10.1007/s00134-024-07737-5.</p><p>Article PubMed Google Scholar </p></li><li data-counter=\"3.\"><p>Ljungman P, Chemaly RF, Khawaya F, Alain S, Avery R, Badshah C, Boeckh M, Fournier M, Hodowanec A, Komatsu T, Limaye AP, Manuel O, Natori Y, Navarro D, Pikis A, Razonable RR, Westman G, Miller V, Griffiths PD, Kotton CN, Hodowanec A, Komatsu T, Piki A, Westman G, Caliendo A, Chou S, Humar A, Randhawa P, Slavin M, Wong M, Wolf D. Consensus definitions of cytomegalovirus (cmv) infection and disease in transplant patients including resistant and refractory cmv for use in clinical trials: 2024 update from the transplant associated virus infections forum. Clin Infect Dis. 2024;79(3):787–94. https://doi.org/10.1093/cid/ciae321.</p><p>Article CAS PubMed PubMed Central Google Scholar </p></li><li data-counter=\"4.\"><p>Papazian L, Hraiech S, Lehingue S, et al. Cytomegalovirus reactivation in ICU patients[J]. Intensive Care Med. 2016;42(1):28–37. https://doi.org/10.1007/s00134-015-4066-9.</p><p>Article CAS PubMed Google Scholar </p></li><li data-counter=\"5.\"><p>Heininger A, Haeberle H, Fischer I, et al. Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis[J]. Crit Care. 2011;15(2):R77. https://doi.org/10.1186/cc10069.</p><p>Article PubMed PubMed Central Google Scholar </p></li><li data-counter=\"6.\"><p>Marandu T, Dombek M, Cook CH. Impact of cytomegalovirus load on host response to sepsis[J]. Med Microbiol Immunol. 2019;208(3–4):295–303. https://doi.org/10.1007/s00430-019-00603-y.</p><p>Article PubMed Google Scholar </p></li><li data-counter=\"7.\"><p>Zhang Z, Li R, Chen Y, et al. Association between active cytomegalovirus infection and lung fibroproliferation in adult patients with acute respiratory distress syndrome: a retrospective study[J]. BMC Infect Dis. 2022;22(1):788. https://doi.org/10.1186/s12879-022-07747-y.</p><p>Article CAS PubMed PubMed Central Google Scholar </p></li><li data-counter=\"8.\"><p>Cook CH, Zhang Y, McGuinness BJ, et al. Intra-abdominal bacterial infection reactivates latent pulmonary cytomegalovirus in immunocompetent mice[J]. J Infect Dis. 2002;185(10):1395–400. https://doi.org/10.1086/340508.</p><p>Article PubMed Google Scholar </p></li><li data-counter=\"9.\"><p>Li X, Huang Y, Xu Z, et al. Cytomegalovirus infection and outcome in immunocompetent patients in the intensive care unit: a systematic review and meta-analysis[J]. BMC Infect Dis. 2018;18(1):289. https://doi.org/10.1186/s12879-018-3195-5.</p><p>Article CAS PubMed PubMed Central Google Scholar </p></li><li data-counter=\"10.\"><p>Meyer NJ, Prescott HC. Sepsis and septic shock[J]. N Engl J Med. 2024;391(22):2133–46. https://doi.org/10.1056/NEJMra2403213.</p><p>Article CAS PubMed Google Scholar </p></li><li data-counter=\"11.\"><p>Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy[J]. Nat Rev Immunol. 2013;13(12):862–74. https://doi.org/10.1038/nri3552.</p><p>Article CAS PubMed PubMed Central Google Scholar </p></li><li data-counter=\"12.\"><p>Zhang Z, Zhang J, Dai S, et al. Active cytomegalovirus infection in mechanically ventilated patients with sepsis[J]. BMC Infect Dis. 2024;24(1):1405. https://doi.org/10.1186/s12879-024-10304-4.</p><p>Article PubMed PubMed Central Google Scholar </p></li><li data-counter=\"13.\"><p>Unterberg M, Ehrentraut SF, Bracht T, et al. Human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis[J]. Crit Care. 2023;27(1):417. https://doi.org/10.1186/s13054-023-04713-1.</p><p>Article CAS PubMed PubMed Central Google Scholar </p></li><li data-counter=\"14.\"><p>Ong DSY, Chong GM, Chemaly RF, et al. Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression[J]. Clin Microbiol Infect. 2022;28(10):1335–44. https://doi.org/10.1016/j.cmi.2022.05.034.</p><p>Article CAS PubMed Google Scholar </p></li><li data-counter=\"15.\"><p>Zhang Z, Liu X, Sang L, et al. Cytomegalovirus reactivation in immunocompetent mechanical ventilation patients: a prospective observational study[J]. BMC Infect Dis. 2021;21(1):1026. https://doi.org/10.1186/s12879-021-06698-0.</p><p>Article CAS PubMed PubMed Central Google Scholar </p></li></ol><p>Download references<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><p>Not applicable.</p><p>The study was funded by the Noncommunicable Chronic Diseases-National Science and Technology Major Project (Nos. SQ2023AAA031364, SQ2024AAA030480, 2023ZD0517300, 2024ZD0530002, 2024ZD0530000), National Natural Science Foundation of China (No. 82070084), and Science and Technology Program of Guangzhou (Nos. SL2023A04J00179, 2024A04J3312).</p><span>Author notes</span><ol><li><p>Zhihui Zhang and Xuesong Liu are co-first author.</p></li></ol><h3>Authors and Affiliations</h3><ol><li><p>Department of Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China</p><p>Zhihui Zhang, Xuesong Liu, Rong Zhang, Dongdong Liu, Chun Yang, Sibei Chen, Yimin Li & Xiaoqing Liu</p></li></ol><span>Authors</span><ol><li><span>Zhihui Zhang</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Xuesong Liu</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Rong Zhang</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Dongdong Liu</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Chun Yang</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Sibei Chen</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Yimin Li</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Xiaoqing Liu</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li></ol><h3>Contributions</h3><p>ZHZ and XSL wrote the manuscript; ZHZ, XSL, RZ, DDL, CY, and SBC revised the manuscript; XQL and YML reviewed the manuscript. XQL and YML contributed equally to the study. All authors read and approved the final manuscript.</p><h3>Corresponding authors</h3><p>Correspondence to Yimin Li or Xiaoqing Liu.</p><h3>Ethics approval and consent to participate</h3>\n<p>Not applicable.</p>\n<h3>Consent for publication</h3>\n<p>Not applicable.</p>\n<h3>Competing interests</h3>\n<p>The authors declare no competing interests.</p><h3>Publisher's Note</h3><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p><p><b>Open Access</b> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.</p>\n<p>Reprints and permissions</p><img alt=\"Check for updates. Verify currency and authenticity via CrossMark\" height=\"81\" loading=\"lazy\" src=\"data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>\" width=\"57\"/><h3>Cite this article</h3><p>Zhang, Z., Liu, X., Zhang, R. <i>et al.</i> Detection of cytomegalovirus in the lower respiratory tract among patients with critical illness: uncovering enhanced potential benefits. <i>Crit Care</i> <b>29</b>, 209 (2025). https://doi.org/10.1186/s13054-025-05456-x</p><p>Download citation<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><ul data-test=\"publication-history\"><li><p>Received<span>: </span><span><time datetime=\"2025-05-07\">07 May 2025</time></span></p></li><li><p>Accepted<span>: </span><span><time datetime=\"2025-05-09\">09 May 2025</time></span></p></li><li><p>Published<span>: </span><span><time datetime=\"2025-05-23\">23 May 2025</time></span></p></li><li><p>DOI</abbr><span>: </span><span>https://doi.org/10.1186/s13054-025-05456-x</span></p></li></ul><h3>Share this article</h3><p>Anyone you share the following link with will be able to read this content:</p><button data-track=\"click\" data-track-action=\"get shareable link\" data-track-external=\"\" data-track-label=\"button\" type=\"button\">Get shareable link</button><p>Sorry, a shareable link is not currently available for this article.</p><p data-track=\"click\" data-track-action=\"select share url\" data-track-label=\"button\"></p><button data-track=\"click\" data-track-action=\"copy share url\" data-track-external=\"\" data-track-label=\"button\" type=\"button\">Copy to clipboard</button><p> Provided by the Springer Nature SharedIt content-sharing initiative </p>","PeriodicalId":10811,"journal":{"name":"Critical Care","volume":"18 1","pages":""},"PeriodicalIF":8.8000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Detection of cytomegalovirus in the lower respiratory tract among patients with critical illness: uncovering enhanced potential benefits\",\"authors\":\"Zhihui Zhang, Xuesong Liu, Rong Zhang, Dongdong Liu, Chun Yang, Sibei Chen, Yimin Li, Xiaoqing Liu\",\"doi\":\"10.1186/s13054-025-05456-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>We were highly interested in reading the clinical research conducted by Kim et al. [1]. This study is a single-center, retrospective clinical cohort investigation with a large sample size, focusing primarily on the significance of lower respiratory tract (LRT) cytomegalovirus (CMV) positivity in the prognosis of critically ill patients. The research departs from the traditional focus on CMV reactivation in blood samples and examines the epidemiological characteristics of critically ill patients with CMV positivity in the LRT. These findings demonstrate CMV positivity in the LRT as a significant risk factor for mortality in patients with critical illness. However, the detection of CMV positivity in the LRT may hold greater significance, and the comprehensiveness of this study could be further enhanced through additional refinements.</p><p>First, the direct definition of CMV detection positivity in the LRT as “reactivation” is debatable. Current CMV-related definitions do not explicitly address this issue [2, 3]. Moreover, the prevailing view is that “reactivation” should be defined based on the premise of CMV seropositivity (IgG) and the detection of a certain CMV viral load in blood samples [2,3,4]. Therefore, the term “CMV detection positivity” is more accurate. Additionally, the CMV viral load may vary among different LRT specimens. Theoretically, the CMV viral load in bronchoalveolar lavage fluid is higher than that in endotracheal aspirates, which may subsequently have different impacts on clinical outcomes. It is necessary to further evaluate the CMV detection positivity and viral load in different LRT specimens and their associations with clinical outcomes.</p><p>Second, of particular importance is the observation that CMV detection in the LRT precede its detection in the blood, especially in patients with septic shock [4, 5]. This phenomenon is likely attributed to the high levels of inflammation associated with sepsis. Under conditions of elevated inflammation, latent CMV infection can be reactivated, subsequently leading to CMV-related injury [6]. Notably, clinical studies have demonstrated a close association between CMV reactivation and pulmonary fibrosis in patients with acute respiratory distress syndrome [7], while animal studies have shown that CMV reactivation can induce pulmonary fibroproliferation [8], suggesting that CMV reactivation may trigger lung injury. Therefore, assessing CMV antiviral therapy based on the LRT findings may hold greater value, including both prophylactic and preemptive treatment strategies.</p><p>Third, subgroup analyses should be conducted to distinguish patients with different immune statuses, including immunosuppressed and non-immunosuppressed individuals, because the incidence of active CMV infection varies across different immune backgrounds, particularly with a higher rate observed in immunosuppressed patients [2,3,4, 9]. Sepsis patients, who are in an acute state of immunosuppression, merit special attention [10]. In this study, the incidence of sepsis exceeded 70%, and high levels of inflammation were found to be more likely to trigger reactivation of latent CMV infection. The early stages (overwhelming inflammation) and the later stages (refractory inflammation, immunosuppression, and risk of secondary infections) of sepsis are both conducive to CMV reactivation [10,11,12,13,14]. Our research demonstrates that the incidence of CMV reactivation is at least 30% higher among critically ill patients with sepsis compared to those without, and sepsis has been identified as an independent risk factor for CMV reactivation [9, 15].</p><p>Fourth, the issue of CMV co-infection with other pathogens should be addressed by employing next-generation sequencing of pathogens to enhance the accuracy of pathogen detection. It is also necessary to distinguish between CMV and colonizing or pathogenic bacteria. In addition, the impact of combined antiviral treatment against CMV and therapy for other pathogens on prognosis needs to be further clarified. Decades of research have shown that CMV infection and reactivation have a negative impact on critically ill patients. Nevertheless, our understanding of the role of CMV positivity in different specimens remains limited. Therefore, we believe that in-depth research into CMV detection in the LRT is of significant importance.</p><p>In summary, the study by Kim et al. revealed the adverse clinical outcomes associated with the detection of CMV in the LRT among critically ill patients, thereby contributing to the advancement of the field. A detailed and nuanced exploration of the aforementioned issues is crucial for fully elucidating the complex interplay between LRT CMV positivity and the prognosis of critically ill patients. Future studies should further investigate these complexities to refine our understanding and potentially guide the development of more effective therapeutic strategies.</p><p>No datasets were generated or analysed during the current study.</p><dl><dt style=\\\"min-width:50px;\\\"><dfn>CMV:</dfn></dt><dd>\\n<p>Cytomegalovirus</p>\\n</dd><dt style=\\\"min-width:50px;\\\"><dfn>LRT:</dfn></dt><dd>\\n<p>Lower Respiratory Tract</p>\\n</dd></dl><ol data-track-component=\\\"outbound reference\\\" data-track-context=\\\"references section\\\"><li data-counter=\\\"1.\\\"><p>Kim JY, Lee CM, Ahn YH, et al. Cytomegalovirus reactivation in the lower respiratory tract as an independent risk factor for mortality in critically ill patients[J]. Crit Care. 2025;29(1):177. https://doi.org/10.1186/s13054-025-05324-8.</p><p>Article PubMed PubMed Central Google Scholar </p></li><li data-counter=\\\"2.\\\"><p>Fernández S, Castro P, Azoulay E. What intensivists need to know about cytomegalovirus infection in immunocompromised ICU patients[J]. Intensive Care Med. 2025;51(1):39–61. https://doi.org/10.1007/s00134-024-07737-5.</p><p>Article PubMed Google Scholar </p></li><li data-counter=\\\"3.\\\"><p>Ljungman P, Chemaly RF, Khawaya F, Alain S, Avery R, Badshah C, Boeckh M, Fournier M, Hodowanec A, Komatsu T, Limaye AP, Manuel O, Natori Y, Navarro D, Pikis A, Razonable RR, Westman G, Miller V, Griffiths PD, Kotton CN, Hodowanec A, Komatsu T, Piki A, Westman G, Caliendo A, Chou S, Humar A, Randhawa P, Slavin M, Wong M, Wolf D. Consensus definitions of cytomegalovirus (cmv) infection and disease in transplant patients including resistant and refractory cmv for use in clinical trials: 2024 update from the transplant associated virus infections forum. Clin Infect Dis. 2024;79(3):787–94. https://doi.org/10.1093/cid/ciae321.</p><p>Article CAS PubMed PubMed Central Google Scholar </p></li><li data-counter=\\\"4.\\\"><p>Papazian L, Hraiech S, Lehingue S, et al. Cytomegalovirus reactivation in ICU patients[J]. Intensive Care Med. 2016;42(1):28–37. https://doi.org/10.1007/s00134-015-4066-9.</p><p>Article CAS PubMed Google Scholar </p></li><li data-counter=\\\"5.\\\"><p>Heininger A, Haeberle H, Fischer I, et al. Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis[J]. Crit Care. 2011;15(2):R77. https://doi.org/10.1186/cc10069.</p><p>Article PubMed PubMed Central Google Scholar </p></li><li data-counter=\\\"6.\\\"><p>Marandu T, Dombek M, Cook CH. Impact of cytomegalovirus load on host response to sepsis[J]. Med Microbiol Immunol. 2019;208(3–4):295–303. https://doi.org/10.1007/s00430-019-00603-y.</p><p>Article PubMed Google Scholar </p></li><li data-counter=\\\"7.\\\"><p>Zhang Z, Li R, Chen Y, et al. Association between active cytomegalovirus infection and lung fibroproliferation in adult patients with acute respiratory distress syndrome: a retrospective study[J]. BMC Infect Dis. 2022;22(1):788. https://doi.org/10.1186/s12879-022-07747-y.</p><p>Article CAS PubMed PubMed Central Google Scholar </p></li><li data-counter=\\\"8.\\\"><p>Cook CH, Zhang Y, McGuinness BJ, et al. Intra-abdominal bacterial infection reactivates latent pulmonary cytomegalovirus in immunocompetent mice[J]. J Infect Dis. 2002;185(10):1395–400. https://doi.org/10.1086/340508.</p><p>Article PubMed Google Scholar </p></li><li data-counter=\\\"9.\\\"><p>Li X, Huang Y, Xu Z, et al. Cytomegalovirus infection and outcome in immunocompetent patients in the intensive care unit: a systematic review and meta-analysis[J]. BMC Infect Dis. 2018;18(1):289. https://doi.org/10.1186/s12879-018-3195-5.</p><p>Article CAS PubMed PubMed Central Google Scholar </p></li><li data-counter=\\\"10.\\\"><p>Meyer NJ, Prescott HC. Sepsis and septic shock[J]. N Engl J Med. 2024;391(22):2133–46. https://doi.org/10.1056/NEJMra2403213.</p><p>Article CAS PubMed Google Scholar </p></li><li data-counter=\\\"11.\\\"><p>Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy[J]. Nat Rev Immunol. 2013;13(12):862–74. https://doi.org/10.1038/nri3552.</p><p>Article CAS PubMed PubMed Central Google Scholar </p></li><li data-counter=\\\"12.\\\"><p>Zhang Z, Zhang J, Dai S, et al. Active cytomegalovirus infection in mechanically ventilated patients with sepsis[J]. BMC Infect Dis. 2024;24(1):1405. https://doi.org/10.1186/s12879-024-10304-4.</p><p>Article PubMed PubMed Central Google Scholar </p></li><li data-counter=\\\"13.\\\"><p>Unterberg M, Ehrentraut SF, Bracht T, et al. Human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis[J]. Crit Care. 2023;27(1):417. https://doi.org/10.1186/s13054-023-04713-1.</p><p>Article CAS PubMed PubMed Central Google Scholar </p></li><li data-counter=\\\"14.\\\"><p>Ong DSY, Chong GM, Chemaly RF, et al. Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression[J]. Clin Microbiol Infect. 2022;28(10):1335–44. https://doi.org/10.1016/j.cmi.2022.05.034.</p><p>Article CAS PubMed Google Scholar </p></li><li data-counter=\\\"15.\\\"><p>Zhang Z, Liu X, Sang L, et al. Cytomegalovirus reactivation in immunocompetent mechanical ventilation patients: a prospective observational study[J]. BMC Infect Dis. 2021;21(1):1026. https://doi.org/10.1186/s12879-021-06698-0.</p><p>Article CAS PubMed PubMed Central Google Scholar </p></li></ol><p>Download references<svg aria-hidden=\\\"true\\\" focusable=\\\"false\\\" height=\\\"16\\\" role=\\\"img\\\" width=\\\"16\\\"><use xlink:href=\\\"#icon-eds-i-download-medium\\\" xmlns:xlink=\\\"http://www.w3.org/1999/xlink\\\"></use></svg></p><p>Not applicable.</p><p>The study was funded by the Noncommunicable Chronic Diseases-National Science and Technology Major Project (Nos. SQ2023AAA031364, SQ2024AAA030480, 2023ZD0517300, 2024ZD0530002, 2024ZD0530000), National Natural Science Foundation of China (No. 82070084), and Science and Technology Program of Guangzhou (Nos. SL2023A04J00179, 2024A04J3312).</p><span>Author notes</span><ol><li><p>Zhihui Zhang and Xuesong Liu are co-first author.</p></li></ol><h3>Authors and Affiliations</h3><ol><li><p>Department of Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China</p><p>Zhihui Zhang, Xuesong Liu, Rong Zhang, Dongdong Liu, Chun Yang, Sibei Chen, Yimin Li & Xiaoqing Liu</p></li></ol><span>Authors</span><ol><li><span>Zhihui Zhang</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Xuesong Liu</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Rong Zhang</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Dongdong Liu</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Chun Yang</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Sibei Chen</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Yimin Li</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Xiaoqing Liu</span>View author publications<p><span>You can also search for this author in</span><span>PubMed<span> </span>Google Scholar</span></p></li></ol><h3>Contributions</h3><p>ZHZ and XSL wrote the manuscript; ZHZ, XSL, RZ, DDL, CY, and SBC revised the manuscript; XQL and YML reviewed the manuscript. XQL and YML contributed equally to the study. All authors read and approved the final manuscript.</p><h3>Corresponding authors</h3><p>Correspondence to Yimin Li or Xiaoqing Liu.</p><h3>Ethics approval and consent to participate</h3>\\n<p>Not applicable.</p>\\n<h3>Consent for publication</h3>\\n<p>Not applicable.</p>\\n<h3>Competing interests</h3>\\n<p>The authors declare no competing interests.</p><h3>Publisher's Note</h3><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p><p><b>Open Access</b> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.</p>\\n<p>Reprints and permissions</p><img alt=\\\"Check for updates. Verify currency and authenticity via CrossMark\\\" height=\\\"81\\\" loading=\\\"lazy\\\" src=\\\"data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>\\\" width=\\\"57\\\"/><h3>Cite this article</h3><p>Zhang, Z., Liu, X., Zhang, R. <i>et al.</i> Detection of cytomegalovirus in the lower respiratory tract among patients with critical illness: uncovering enhanced potential benefits. <i>Crit Care</i> <b>29</b>, 209 (2025). https://doi.org/10.1186/s13054-025-05456-x</p><p>Download citation<svg aria-hidden=\\\"true\\\" focusable=\\\"false\\\" height=\\\"16\\\" role=\\\"img\\\" width=\\\"16\\\"><use xlink:href=\\\"#icon-eds-i-download-medium\\\" xmlns:xlink=\\\"http://www.w3.org/1999/xlink\\\"></use></svg></p><ul data-test=\\\"publication-history\\\"><li><p>Received<span>: </span><span><time datetime=\\\"2025-05-07\\\">07 May 2025</time></span></p></li><li><p>Accepted<span>: </span><span><time datetime=\\\"2025-05-09\\\">09 May 2025</time></span></p></li><li><p>Published<span>: </span><span><time datetime=\\\"2025-05-23\\\">23 May 2025</time></span></p></li><li><p>DOI</abbr><span>: </span><span>https://doi.org/10.1186/s13054-025-05456-x</span></p></li></ul><h3>Share this article</h3><p>Anyone you share the following link with will be able to read this content:</p><button data-track=\\\"click\\\" data-track-action=\\\"get shareable link\\\" data-track-external=\\\"\\\" data-track-label=\\\"button\\\" type=\\\"button\\\">Get shareable link</button><p>Sorry, a shareable link is not currently available for this article.</p><p data-track=\\\"click\\\" data-track-action=\\\"select share url\\\" data-track-label=\\\"button\\\"></p><button data-track=\\\"click\\\" data-track-action=\\\"copy share url\\\" data-track-external=\\\"\\\" data-track-label=\\\"button\\\" type=\\\"button\\\">Copy to clipboard</button><p> Provided by the Springer Nature SharedIt content-sharing initiative </p>\",\"PeriodicalId\":10811,\"journal\":{\"name\":\"Critical Care\",\"volume\":\"18 1\",\"pages\":\"\"},\"PeriodicalIF\":8.8000,\"publicationDate\":\"2025-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Critical Care\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13054-025-05456-x\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13054-025-05456-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0
摘要
我们对Kim等人的临床研究非常感兴趣。本研究为单中心、大样本量的回顾性临床队列研究,主要探讨下呼吸道巨细胞病毒(CMV)阳性对危重患者预后的影响。本研究改变了传统的血液样本中巨细胞病毒再激活的研究重点,探讨了LRT中巨细胞病毒阳性危重患者的流行病学特征。这些发现表明,下呼吸道巨细胞病毒阳性是重症患者死亡的一个重要危险因素。然而,在LRT中检测CMV阳性可能具有更大的意义,本研究的全面性可以通过进一步的完善来进一步增强。首先,将LRT中CMV检测阳性直接定义为“再激活”是有争议的。当前cmv相关的定义没有明确地解决这个问题[2,3]。此外,目前流行的观点认为,“再激活”的定义应以CMV血清阳性(IgG)和血液样本中检测到一定的CMV病毒载量为前提[2,3,4]。因此,“CMV检测阳性”一词更为准确。此外,CMV病毒载量可能在不同的LRT标本中有所不同。理论上,支气管肺泡灌洗液中的CMV病毒载量高于气管内吸入液,这可能对临床结果产生不同的影响。有必要进一步评估不同LRT标本的CMV检测阳性和病毒载量及其与临床结果的关系。其次,特别重要的是观察到LRT中CMV的检测先于其在血液中的检测,特别是在脓毒性休克患者中[4,5]。这种现象可能归因于与败血症相关的高水平炎症。在炎症升高的情况下,潜伏的巨细胞病毒感染可被重新激活,随后导致巨细胞病毒相关损伤[6]。值得注意的是,临床研究表明CMV再激活与急性呼吸窘迫综合征[7]患者的肺纤维化密切相关,而动物研究表明CMV再激活可诱导肺纤维增生[8],提示CMV再激活可能引发肺损伤。因此,基于LRT结果评估CMV抗病毒治疗可能具有更大的价值,包括预防和先发制人的治疗策略。第三,应进行亚组分析,以区分不同免疫状态的患者,包括免疫抑制和非免疫抑制个体,因为不同免疫背景的患者活动性巨细胞病毒感染的发生率不同,特别是免疫抑制患者的发生率更高[2,3,4,9]。脓毒症患者处于急性免疫抑制状态,值得特别关注。在本研究中,败血症的发生率超过70%,并且发现高水平的炎症更容易触发潜伏CMV感染的再激活。败血症的早期(压倒性炎症)和晚期(难治性炎症、免疫抑制和继发感染的风险)都有利于CMV的再激活[10,11,12,13,14]。我们的研究表明,脓毒症危重患者CMV再激活的发生率比无脓毒症危重患者至少高出30%,脓毒症已被确定为CMV再激活的独立危险因素[9,15]。第四,解决巨细胞病毒与其他病原体共感染的问题,采用新一代病原体测序技术,提高病原体检测的准确性。也有必要区分巨细胞病毒和定殖或致病菌。此外,CMV抗病毒联合治疗和其他病原体治疗对预后的影响还有待进一步明确。数十年的研究表明,巨细胞病毒感染和再激活对危重患者有负面影响。然而,我们对CMV阳性在不同标本中的作用的理解仍然有限。因此,我们认为深入研究CMV在LRT中的检测具有重要意义。总之,Kim等人的研究揭示了危重患者在LRT中检测巨细胞病毒相关的不良临床结果,从而促进了该领域的发展。对上述问题进行详细和细致的探讨对于充分阐明LRT CMV阳性与危重患者预后之间复杂的相互作用至关重要。未来的研究应该进一步调查这些复杂性,以完善我们的理解,并有可能指导更有效的治疗策略的发展。在本研究中没有生成或分析数据集。 CMV:巨细胞病毒lrt:下呼吸道下呼吸道巨细胞病毒再激活对危重患者死亡的影响[J]。危重症护理,2025;29(1):177。https://doi.org/10.1186/s13054-025-05324-8.Article PubMed PubMed Central bbb [0] Scholar Fernández,王晓明,王晓明,等。免疫功能低下重症监护室患者巨细胞病毒感染的临床分析[J]。重症监护医学,2025;51(1):39-61。https://doi.org/10.1007/s00134-024-07737-5.Article PubMed谷歌Scholar Ljungman P, Chemaly RF, Khawaya F, Alain S, Avery R, Badshah C, Boeckh M, Fournier M, Hodowanec A, Komatsu T, Limaye AP, Manuel O, Natori Y, Navarro D, Pikis A, Razonable RR, Westman G, Miller V, Griffiths PD, Kotton CN, Hodowanec A, Komatsu T, Piki A, Westman G, Caliendo A, Chou S, Humar A, Randhawa P, Slavin M, Wong M,移植患者巨细胞病毒(cmv)感染和疾病的共识定义,包括用于临床试验的耐药和难治性巨细胞病毒:2024年移植相关病毒感染论坛的更新。中华临床传染病杂志,2009;79(3):787-94。https://doi.org/10.1093/cid/ciae321.Article CAS PubMed PubMed Central谷歌学者Papazian L, Hraiech S, Lehingue S,等。重症监护病房患者巨细胞病毒再激活[J]。重症监护医学,2016;42(1):28-37。https://doi.org/10.1007/s00134-015-4066-9.Article CAS PubMed谷歌学者Heininger A, Haeberle H, Fischer I,等。重症脓毒症患者巨细胞病毒再激活与预后的关系[J]。危重症护理,2011;15(2):R77。https://doi.org/10.1186/cc10069.Article PubMed PubMed Central [J].学者马兰杜,王晓明,王晓明,等。巨细胞病毒载量对脓毒症患者免疫应答的影响[J]。中国生物医学工程学报,2019;32(3):559 - 563。https://doi.org/10.1007/s00430-019-00603-y.Article PubMed谷歌学者张志,李睿,陈勇,等。急性呼吸窘迫综合征患者巨细胞病毒活动性感染与肺纤维增生的相关性研究[J]。中国生物医学工程学报,2016;22(1):788。https://doi.org/10.1186/s12879-022-07747-y.Article CAS PubMed PubMed Central谷歌学者Cook CH, Zhang Y, McGuinness BJ,等。腹腔细菌感染对肺巨细胞病毒的激活作用[J]。中华流行病学杂志,2002;18(3):391 - 391。https://doi.org/10.1086/340508.Article PubMed谷歌学者李旭,黄毅,徐铮,等。重症监护病房免疫功能正常患者巨细胞病毒感染与预后的meta分析[J]。中国传染病杂志,2018;18(1):289。https://doi.org/10.1186/s12879-018-3195-5.Article CAS PubMed PubMed Central谷歌学者Meyer NJ, Prescott HC。脓毒症与感染性休克[J]。中华医学杂志,2009;31(2):393 - 394。[0]王晓明,王晓明,王晓明,等。脓毒症诱导免疫抑制的研究进展[J]。中华免疫学杂志,2013;13(12):862-74。https://doi.org/10.1038/nri3552.Article CAS PubMed PubMed Central谷歌学者张志,张杰,戴胜,等。脓毒症机械通气患者巨细胞病毒感染的分析[J]。中国生物医学工程学报,2014;24(1):1405。https://doi.org/10.1186/s12879-024-10304-4.Article PubMed PubMed Central谷歌学者Unterberg M, Ehrentraut SF, Bracht T,等。人巨细胞病毒血清阳性与脓毒症患者生存率的关系[J]。危重症护理,2013;27(1):417。https://doi.org/10.1186/s13054-023-04713-1.Article CAS PubMed PubMed Central谷歌学者王德赛,Chong GM, Chemaly RF,等。不同类型免疫抑制后巨细胞病毒感染的临床表现及免疫效果比较[J]。中华临床微生物学杂志,2022;28(10):1335-44。https://doi.org/10.1016/j.cmi.2022.05.034.Article中科院PubMed谷歌学者张志,刘旭,桑林,等。免疫功能机械通气患者巨细胞病毒再激活的前瞻性观察[J]。中华传染病杂志,2013;21(1):1026。https://doi.org/10.1186/s12879-021-06698-0.Article CAS PubMed PubMed Central谷歌学者下载参考文献不适用。非传染性慢性病国家科技重大专项(No. SQ2023AAA031364, SQ2024AAA030480, 2023ZD0517300, 2024ZD0530002, 2024ZD0530000),国家自然科学基金项目(No. 82070084),广州市科技计划项目(No. SL2023A04J00179, 2024A04J3312)资助。作者说明:张志辉和刘雪松共同为第一作者。 中华人民共和国广东省广州市广州医科大学第一附属医院,国家呼吸医学中心,国家呼吸疾病临床研究中心,广州呼吸健康研究所,呼吸疾病国家重点实验室,重症医学科,张志辉,刘雪松,张荣,刘东东,杨春,陈思北,李益民等;刘晓青authorszhangzhihui查看作者出版物您也可以在pubmed谷歌scholar雪松查看作者出版物您也可以在pubmed谷歌ScholarRong zhang雪松查看作者出版物您也可以在pubmed谷歌ScholarDongdong liudongdong查看作者出版物您也可以在pubmed谷歌ScholarSibei查看作者出版物您也可以在pubmed谷歌ScholarSibei查看作者出版物ChenView作者publications您也可以在pubmed b谷歌ScholarYimin LiView作者publications您也可以在pubmed谷歌ScholarXiaoqing LiuView作者publications您也可以在pubmed谷歌ScholarContributionsZHZ和XSL撰写的稿件中搜索该作者;ZHZ、XSL、RZ、DDL、CY、SBC修改稿件;XQL和YML审阅了手稿。XQL和YML对研究的贡献相同。所有作者都阅读并批准了最终的手稿。通讯作者李益民刘晓青。对参与者的伦理批准和同意不适用。发表同意不适用。利益竞争作者声明没有利益竞争。出版商声明:对于已出版的地图和机构关系中的管辖权要求,普林格·自然保持中立。开放获取本文遵循知识共享署名-非商业-非衍生品4.0国际许可协议,该协议允许以任何媒介或格式进行非商业用途、共享、分发和复制,只要您适当注明原作者和来源,提供知识共享许可协议的链接,并注明您是否修改了许可材料。根据本许可协议,您无权分享源自本文或其部分内容的改编材料。本文中的图像或其他第三方材料包含在文章的知识共享许可协议中,除非在材料的署名中另有说明。如果材料未包含在文章的知识共享许可中,并且您的预期用途不被法律法规允许或超过允许的用途,您将需要直接获得版权所有者的许可。要查看该许可协议的副本,请访问http://creativecommons.org/licenses/by-nc-nd/4.0/.Reprints和permissionsCite这篇文章。危重患者下呼吸道巨细胞病毒检测:揭示增强的潜在益处危重护理29,209(2025)。https://doi.org/10.1186/s13054-025-05456-xDownload citation:收稿日期:2025年5月7日接受日期:2025年5月9日发布日期:2025年5月23日doi: https://doi.org/10.1186/s13054-025-05456-xShare这篇文章任何你分享以下链接的人都可以阅读到这篇文章:获取可共享链接对不起,这篇文章目前没有可共享链接。复制到剪贴板由施普林格自然共享内容倡议提供
Detection of cytomegalovirus in the lower respiratory tract among patients with critical illness: uncovering enhanced potential benefits
We were highly interested in reading the clinical research conducted by Kim et al. [1]. This study is a single-center, retrospective clinical cohort investigation with a large sample size, focusing primarily on the significance of lower respiratory tract (LRT) cytomegalovirus (CMV) positivity in the prognosis of critically ill patients. The research departs from the traditional focus on CMV reactivation in blood samples and examines the epidemiological characteristics of critically ill patients with CMV positivity in the LRT. These findings demonstrate CMV positivity in the LRT as a significant risk factor for mortality in patients with critical illness. However, the detection of CMV positivity in the LRT may hold greater significance, and the comprehensiveness of this study could be further enhanced through additional refinements.
First, the direct definition of CMV detection positivity in the LRT as “reactivation” is debatable. Current CMV-related definitions do not explicitly address this issue [2, 3]. Moreover, the prevailing view is that “reactivation” should be defined based on the premise of CMV seropositivity (IgG) and the detection of a certain CMV viral load in blood samples [2,3,4]. Therefore, the term “CMV detection positivity” is more accurate. Additionally, the CMV viral load may vary among different LRT specimens. Theoretically, the CMV viral load in bronchoalveolar lavage fluid is higher than that in endotracheal aspirates, which may subsequently have different impacts on clinical outcomes. It is necessary to further evaluate the CMV detection positivity and viral load in different LRT specimens and their associations with clinical outcomes.
Second, of particular importance is the observation that CMV detection in the LRT precede its detection in the blood, especially in patients with septic shock [4, 5]. This phenomenon is likely attributed to the high levels of inflammation associated with sepsis. Under conditions of elevated inflammation, latent CMV infection can be reactivated, subsequently leading to CMV-related injury [6]. Notably, clinical studies have demonstrated a close association between CMV reactivation and pulmonary fibrosis in patients with acute respiratory distress syndrome [7], while animal studies have shown that CMV reactivation can induce pulmonary fibroproliferation [8], suggesting that CMV reactivation may trigger lung injury. Therefore, assessing CMV antiviral therapy based on the LRT findings may hold greater value, including both prophylactic and preemptive treatment strategies.
Third, subgroup analyses should be conducted to distinguish patients with different immune statuses, including immunosuppressed and non-immunosuppressed individuals, because the incidence of active CMV infection varies across different immune backgrounds, particularly with a higher rate observed in immunosuppressed patients [2,3,4, 9]. Sepsis patients, who are in an acute state of immunosuppression, merit special attention [10]. In this study, the incidence of sepsis exceeded 70%, and high levels of inflammation were found to be more likely to trigger reactivation of latent CMV infection. The early stages (overwhelming inflammation) and the later stages (refractory inflammation, immunosuppression, and risk of secondary infections) of sepsis are both conducive to CMV reactivation [10,11,12,13,14]. Our research demonstrates that the incidence of CMV reactivation is at least 30% higher among critically ill patients with sepsis compared to those without, and sepsis has been identified as an independent risk factor for CMV reactivation [9, 15].
Fourth, the issue of CMV co-infection with other pathogens should be addressed by employing next-generation sequencing of pathogens to enhance the accuracy of pathogen detection. It is also necessary to distinguish between CMV and colonizing or pathogenic bacteria. In addition, the impact of combined antiviral treatment against CMV and therapy for other pathogens on prognosis needs to be further clarified. Decades of research have shown that CMV infection and reactivation have a negative impact on critically ill patients. Nevertheless, our understanding of the role of CMV positivity in different specimens remains limited. Therefore, we believe that in-depth research into CMV detection in the LRT is of significant importance.
In summary, the study by Kim et al. revealed the adverse clinical outcomes associated with the detection of CMV in the LRT among critically ill patients, thereby contributing to the advancement of the field. A detailed and nuanced exploration of the aforementioned issues is crucial for fully elucidating the complex interplay between LRT CMV positivity and the prognosis of critically ill patients. Future studies should further investigate these complexities to refine our understanding and potentially guide the development of more effective therapeutic strategies.
No datasets were generated or analysed during the current study.
CMV:
Cytomegalovirus
LRT:
Lower Respiratory Tract
Kim JY, Lee CM, Ahn YH, et al. Cytomegalovirus reactivation in the lower respiratory tract as an independent risk factor for mortality in critically ill patients[J]. Crit Care. 2025;29(1):177. https://doi.org/10.1186/s13054-025-05324-8.
Article PubMed PubMed Central Google Scholar
Fernández S, Castro P, Azoulay E. What intensivists need to know about cytomegalovirus infection in immunocompromised ICU patients[J]. Intensive Care Med. 2025;51(1):39–61. https://doi.org/10.1007/s00134-024-07737-5.
Article PubMed Google Scholar
Ljungman P, Chemaly RF, Khawaya F, Alain S, Avery R, Badshah C, Boeckh M, Fournier M, Hodowanec A, Komatsu T, Limaye AP, Manuel O, Natori Y, Navarro D, Pikis A, Razonable RR, Westman G, Miller V, Griffiths PD, Kotton CN, Hodowanec A, Komatsu T, Piki A, Westman G, Caliendo A, Chou S, Humar A, Randhawa P, Slavin M, Wong M, Wolf D. Consensus definitions of cytomegalovirus (cmv) infection and disease in transplant patients including resistant and refractory cmv for use in clinical trials: 2024 update from the transplant associated virus infections forum. Clin Infect Dis. 2024;79(3):787–94. https://doi.org/10.1093/cid/ciae321.
Article CAS PubMed PubMed Central Google Scholar
Papazian L, Hraiech S, Lehingue S, et al. Cytomegalovirus reactivation in ICU patients[J]. Intensive Care Med. 2016;42(1):28–37. https://doi.org/10.1007/s00134-015-4066-9.
Article CAS PubMed Google Scholar
Heininger A, Haeberle H, Fischer I, et al. Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis[J]. Crit Care. 2011;15(2):R77. https://doi.org/10.1186/cc10069.
Article PubMed PubMed Central Google Scholar
Marandu T, Dombek M, Cook CH. Impact of cytomegalovirus load on host response to sepsis[J]. Med Microbiol Immunol. 2019;208(3–4):295–303. https://doi.org/10.1007/s00430-019-00603-y.
Article PubMed Google Scholar
Zhang Z, Li R, Chen Y, et al. Association between active cytomegalovirus infection and lung fibroproliferation in adult patients with acute respiratory distress syndrome: a retrospective study[J]. BMC Infect Dis. 2022;22(1):788. https://doi.org/10.1186/s12879-022-07747-y.
Article CAS PubMed PubMed Central Google Scholar
Cook CH, Zhang Y, McGuinness BJ, et al. Intra-abdominal bacterial infection reactivates latent pulmonary cytomegalovirus in immunocompetent mice[J]. J Infect Dis. 2002;185(10):1395–400. https://doi.org/10.1086/340508.
Article PubMed Google Scholar
Li X, Huang Y, Xu Z, et al. Cytomegalovirus infection and outcome in immunocompetent patients in the intensive care unit: a systematic review and meta-analysis[J]. BMC Infect Dis. 2018;18(1):289. https://doi.org/10.1186/s12879-018-3195-5.
Article CAS PubMed PubMed Central Google Scholar
Meyer NJ, Prescott HC. Sepsis and septic shock[J]. N Engl J Med. 2024;391(22):2133–46. https://doi.org/10.1056/NEJMra2403213.
Article CAS PubMed Google Scholar
Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy[J]. Nat Rev Immunol. 2013;13(12):862–74. https://doi.org/10.1038/nri3552.
Article CAS PubMed PubMed Central Google Scholar
Zhang Z, Zhang J, Dai S, et al. Active cytomegalovirus infection in mechanically ventilated patients with sepsis[J]. BMC Infect Dis. 2024;24(1):1405. https://doi.org/10.1186/s12879-024-10304-4.
Article PubMed PubMed Central Google Scholar
Unterberg M, Ehrentraut SF, Bracht T, et al. Human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis[J]. Crit Care. 2023;27(1):417. https://doi.org/10.1186/s13054-023-04713-1.
Article CAS PubMed PubMed Central Google Scholar
Ong DSY, Chong GM, Chemaly RF, et al. Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression[J]. Clin Microbiol Infect. 2022;28(10):1335–44. https://doi.org/10.1016/j.cmi.2022.05.034.
Article CAS PubMed Google Scholar
Zhang Z, Liu X, Sang L, et al. Cytomegalovirus reactivation in immunocompetent mechanical ventilation patients: a prospective observational study[J]. BMC Infect Dis. 2021;21(1):1026. https://doi.org/10.1186/s12879-021-06698-0.
Article CAS PubMed PubMed Central Google Scholar
Download references
Not applicable.
The study was funded by the Noncommunicable Chronic Diseases-National Science and Technology Major Project (Nos. SQ2023AAA031364, SQ2024AAA030480, 2023ZD0517300, 2024ZD0530002, 2024ZD0530000), National Natural Science Foundation of China (No. 82070084), and Science and Technology Program of Guangzhou (Nos. SL2023A04J00179, 2024A04J3312).
Author notes
Zhihui Zhang and Xuesong Liu are co-first author.
Authors and Affiliations
Department of Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China
Zhihui Zhang, Xuesong Liu, Rong Zhang, Dongdong Liu, Chun Yang, Sibei Chen, Yimin Li & Xiaoqing Liu
Authors
Zhihui ZhangView author publications
You can also search for this author inPubMedGoogle Scholar
Xuesong LiuView author publications
You can also search for this author inPubMedGoogle Scholar
Rong ZhangView author publications
You can also search for this author inPubMedGoogle Scholar
Dongdong LiuView author publications
You can also search for this author inPubMedGoogle Scholar
Chun YangView author publications
You can also search for this author inPubMedGoogle Scholar
Sibei ChenView author publications
You can also search for this author inPubMedGoogle Scholar
Yimin LiView author publications
You can also search for this author inPubMedGoogle Scholar
Xiaoqing LiuView author publications
You can also search for this author inPubMedGoogle Scholar
Contributions
ZHZ and XSL wrote the manuscript; ZHZ, XSL, RZ, DDL, CY, and SBC revised the manuscript; XQL and YML reviewed the manuscript. XQL and YML contributed equally to the study. All authors read and approved the final manuscript.
Corresponding authors
Correspondence to Yimin Li or Xiaoqing Liu.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Reprints and permissions
Cite this article
Zhang, Z., Liu, X., Zhang, R. et al. Detection of cytomegalovirus in the lower respiratory tract among patients with critical illness: uncovering enhanced potential benefits. Crit Care29, 209 (2025). https://doi.org/10.1186/s13054-025-05456-x
Download citation
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s13054-025-05456-x
Share this article
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
期刊介绍:
Critical Care is an esteemed international medical journal that undergoes a rigorous peer-review process to maintain its high quality standards. Its primary objective is to enhance the healthcare services offered to critically ill patients. To achieve this, the journal focuses on gathering, exchanging, disseminating, and endorsing evidence-based information that is highly relevant to intensivists. By doing so, Critical Care seeks to provide a thorough and inclusive examination of the intensive care field.